| abstract |
Disclosed in the present invention are quinine compounds, and pharmaceutically acceptable salts, solvates, precursors and optical isomers thereof. Also disclosed in the present invention are that the above compounds have a selective blocking effect on the receptor subtypes M 1 and M 3 , but have no significant effect on the M 2 receptor; and the above compounds have the characteristics of rapid action, long efficacy and low toxicity when used to treat rhinitis, post-cold rhinitis, chronic bronchitis, airway hyperresponsiveness, asthma, chronic obstructive pulmonary diseases, coughs, urinary incontinence, frequent urination, overactive bladder syndrome, bladder spasms, bladder inflammation and gastrointestinal disorders, such as acute bowel syndrome, spastic colitis as well as duodenal and gastric ulcers. |